Oak Thistle LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,031 shares of the company's stock, valued at approximately $426,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after buying an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC raised its position in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock valued at $34,000 after buying an additional 60 shares during the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in shares of IDEXX Laboratories in the second quarter valued at about $36,000. Finally, Ashton Thomas Securities LLC acquired a new stake in IDEXX Laboratories during the third quarter worth about $37,000. Institutional investors own 87.84% of the company's stock.
Wall Street Analyst Weigh In
IDXX has been the subject of several recent research reports. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, November 28th. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. Piper Sandler reissued a "neutral" rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, Barclays reduced their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a report on Monday, November 4th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $539.63.
Read Our Latest Analysis on IDEXX Laboratories
Insiders Place Their Bets
In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now owns 905 shares of the company's stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.18% of the company's stock.
IDEXX Laboratories Price Performance
IDEXX Laboratories stock traded down $9.36 during trading hours on Friday, hitting $419.26. 798,777 shares of the stock were exchanged, compared to its average volume of 553,025. The stock has a market capitalization of $34.33 billion, a P/E ratio of 40.43, a P/E/G ratio of 3.52 and a beta of 1.36. The business's 50-day moving average is $423.88 and its two-hundred day moving average is $458.53. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to analysts' expectations of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business's revenue was up 6.6% on a year-over-year basis. During the same period last year, the firm posted $2.53 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Articles
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
